Table 3. Postoperative outcomes comparing CGCRYODERM versus DermACELL.

	CGCRYODERM (n=32)	DermACELL (n=32)	P value
Overall complication, n (%), [events]	4 (12.50) [5]	5 (15.63) [8]	0.7055
Major* complication, n (%), [events]	4 (12.50) [5]	4 (12.50) [7]	1.0000
Seroma, n (%)	1 (3.13)	2 (6.25)	0.5637
Major*, n (%)	1 (3.13)	2 (6.25)	0.5637
Infection, n (%)	1 (3.13)	4 (12.50)	0.1797
Major*, n (%)	1 (3.13)	3 (9.38)	0.3173
Hematoma, n (%)	1 (3.13)	1 (3.13)	1.0000
Major*, n (%)	1 (3.13)	1 (3.13)	1.0000
Mastectomy flap necrosis, n (%)	2 (6.25)	1 (3.13)	0.3173
Major*, n (%)	2 (6.25)	1 (3.13)	0.3173
Reconstructive failure, n (%)	0 (0.00)	0 (0.00)	–

*, requiring unplanned readmission and/or reoperation after discharge for any complication.